Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06181032 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies

Name: A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies — clinical trial record (NCT06181032)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorFirst Affiliated Hospital of Fujian Medical University

Started2023-12-23

View on ClinicalTrials.gov ↗

Amendment history

2024-04-27

Study Status, Arms and Interventions v2

InterventionsAdebrelimab (Drug)→Adebrelimab (Drug), Apatinib (Drug), Cisplatin (Drug), Gemcitabine (Drug)

2024-02-27

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Study sites0→1

2023-12-21

Original filing

First Affiliated Hospital of Fujian Medical University

56 trials monitored

See all monitored trials

Cholangiocarcinoma

611 trials monitored

See 25 trials at risk

Evaluating the efficacy and safety of adebrelimab in combination with apatinib, gemcitabine and cisplatin in the neoadjuvant treatment of patients with biliary tract malignancies.

Trial Details

NCT Number	NCT06181032
Lead Sponsor	First Affiliated Hospital of Fujian Medical University
Conditions	Biliary Tract Malignancies
Enrollment	35 participants
Start Date	2023-12-23
Primary Completion	2029-02-23 (estimated)
Study Completion	2029-02-23 (estimated)
Updated on ClinicalTrials.gov	2024-04-30